Voyager Therapeutics (NASDAQ:VYGR) was downgraded by investment analysts at Wedbush from an “outperform” rating to a “neutral” rating in a report issued on Monday, March 12th, MarketBeat.com reports. They presently have a $29.00 price target on the stock. Wedbush’s target price would indicate a potential upside of 66.95% from the company’s previous close.
Several other research firms have also recently issued reports on VYGR. BidaskClub upgraded Voyager Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, February 24th. BTIG Research reiterated a “buy” rating and issued a $32.00 price objective on shares of Voyager Therapeutics in a research report on Sunday, March 11th. Piper Jaffray reiterated a “buy” rating and issued a $40.00 price objective on shares of Voyager Therapeutics in a research report on Monday, March 12th. Morgan Stanley raised their price target on Voyager Therapeutics from $36.00 to $39.00 and gave the company an “overweight” rating in a research report on Wednesday, February 21st. Finally, Canaccord Genuity restated a “buy” rating and issued a $26.00 price target on shares of Voyager Therapeutics in a research report on Tuesday, January 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $29.73.
Shares of NASDAQ VYGR opened at $17.37 on Monday. Voyager Therapeutics has a 1-year low of $8.10 and a 1-year high of $31.91. The firm has a market cap of $619.66, a P/E ratio of -6.58 and a beta of 2.97.
In related news, insider Dinah Ph.D. Sah sold 15,623 shares of the business’s stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $30.00, for a total transaction of $468,690.00. Following the completion of the transaction, the insider now owns 140,872 shares in the company, valued at approximately $4,226,160. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Jane Henderson sold 17,316 shares of the business’s stock in a transaction that occurred on Monday, March 19th. The shares were sold at an average price of $22.11, for a total value of $382,856.76. Following the transaction, the chief financial officer now owns 15,416 shares of the company’s stock, valued at approximately $340,847.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 68,087 shares of company stock valued at $1,588,741. 8.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its position in Voyager Therapeutics by 312.8% during the 3rd quarter. Wells Fargo & Company MN now owns 377,190 shares of the company’s stock valued at $7,766,000 after purchasing an additional 285,806 shares during the period. Aevitas Wealth Management Inc. acquired a new position in Voyager Therapeutics during the 4th quarter valued at approximately $1,400,000. Vanguard Group Inc. boosted its position in Voyager Therapeutics by 3.2% during the 2nd quarter. Vanguard Group Inc. now owns 430,765 shares of the company’s stock worth $3,860,000 after acquiring an additional 13,194 shares during the period. Bank of New York Mellon Corp boosted its position in Voyager Therapeutics by 16.2% during the 3rd quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock worth $1,274,000 after acquiring an additional 8,633 shares during the period. Finally, Lazard Asset Management LLC acquired a new position in Voyager Therapeutics during the 4th quarter worth $334,000. Institutional investors and hedge funds own 78.22% of the company’s stock.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.